PL375523A1 - Pochodne chinoliny oraz ich zastosowanie jako inhibitorów prątków - Google Patents

Pochodne chinoliny oraz ich zastosowanie jako inhibitorów prątków

Info

Publication number
PL375523A1
PL375523A1 PL03375523A PL37552303A PL375523A1 PL 375523 A1 PL375523 A1 PL 375523A1 PL 03375523 A PL03375523 A PL 03375523A PL 37552303 A PL37552303 A PL 37552303A PL 375523 A1 PL375523 A1 PL 375523A1
Authority
PL
Poland
Prior art keywords
quinoline derivatives
mycobacterial inhibitors
mycobacterial
inhibitors
quinoline
Prior art date
Application number
PL03375523A
Other languages
English (en)
Other versions
PL222801B1 (pl
Inventor
Gestel Jozef Frans Elisabetha Van
Jerome Emile Georges Guillemont
Marc Gaston Venet
Herve Jean Joseph Poignet
Laurence Francoise Bernadette Decrane
Daniel F.J. Vernier
Frank Christopher Odds
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL375523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL375523A1 publication Critical patent/PL375523A1/pl
Publication of PL222801B1 publication Critical patent/PL222801B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
PL375523A 2002-07-25 2003-07-18 Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je PL222801B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25

Publications (2)

Publication Number Publication Date
PL375523A1 true PL375523A1 (pl) 2005-11-28
PL222801B1 PL222801B1 (pl) 2016-09-30

Family

ID=31188461

Family Applications (1)

Application Number Title Priority Date Filing Date
PL375523A PL222801B1 (pl) 2002-07-25 2003-07-18 Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je

Country Status (37)

Country Link
US (1) US7498343B2 (pl)
EP (2) EP2301544B1 (pl)
JP (1) JP4484703B2 (pl)
KR (1) KR100733577B1 (pl)
CN (2) CN1325475C (pl)
AP (1) AP2421A (pl)
AR (1) AR040673A1 (pl)
AT (1) ATE463482T1 (pl)
AU (1) AU2003262529B2 (pl)
BE (1) BE2014C051I2 (pl)
BR (1) BRPI0312927B8 (pl)
CA (1) CA2493225C (pl)
CY (3) CY1111882T1 (pl)
DE (1) DE60332023D1 (pl)
DK (2) DK1527050T3 (pl)
EA (1) EA008937B1 (pl)
ES (2) ES2343458T3 (pl)
FR (1) FR14C0060I2 (pl)
HR (2) HRP20050045B1 (pl)
HU (1) HUS1400047I1 (pl)
IL (2) IL166457A (pl)
IS (1) IS2914B (pl)
LU (1) LU92520I2 (pl)
ME (1) ME00131B (pl)
MX (1) MXPA05001052A (pl)
MY (1) MY143564A (pl)
NL (1) NL300684I2 (pl)
NO (2) NO329935B1 (pl)
NZ (1) NZ538391A (pl)
PL (1) PL222801B1 (pl)
PT (2) PT1527050E (pl)
RS (1) RS52431B (pl)
SI (2) SI1527050T1 (pl)
TW (1) TWI323730B (pl)
UA (1) UA82198C2 (pl)
WO (1) WO2004011436A1 (pl)
ZA (1) ZA200500680B (pl)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2188A (en) * 2004-01-23 2010-12-14 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors.
PT1711181E (pt) * 2004-01-23 2009-12-29 Janssen Pharmaceutica Nv Derivados quinolina e sua utilização como inibidores micobacterianos
AU2005210036B2 (en) * 2004-01-29 2010-12-23 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
ES2306146T3 (es) * 2004-05-28 2008-11-01 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
RS56357B1 (sr) 2004-09-28 2017-12-29 Janssen Pharmaceutica Nv Vezujući domen bakterijske atp sintaze
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
AU2006251208B2 (en) * 2005-05-25 2012-11-29 Janssen Pharmaceutica N.V. Process for preparing (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
HUE030264T2 (en) * 2005-06-28 2017-04-28 Janssen Pharmaceutica Nv Quinoline derivatives as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
DK2841426T3 (en) 2012-04-27 2017-01-09 Janssen Pharmaceutica Nv ANTIBACTERIAL QUINOLIN DERIVATIVES
EA035443B1 (ru) 2012-04-27 2020-06-17 Янссен Фармацевтика Нв Антибактериальные хинолиновые производные
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
UA117672C2 (uk) 2012-12-21 2018-09-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Антибактеріальні сполуки
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
HK1243644A1 (zh) 2015-01-27 2018-07-20 Janssen Pharmaceutica Nv 可分散组合物
BR112017023448A2 (pt) * 2015-04-29 2018-07-31 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) composições anti-fitopatogênicas
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
MA42293A (fr) 2015-07-02 2018-05-09 Janssen Sciences Ireland Uc Composés antibactériens
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
CN107848978B (zh) * 2015-07-24 2021-04-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
WO2017066926A1 (zh) * 2015-10-20 2017-04-27 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN108699047B (zh) * 2016-03-03 2022-03-11 科学与工业研究委员会 作为抗分枝杆菌药剂的取代的橙酮生物碱
KR102355154B1 (ko) * 2016-03-07 2022-01-26 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 항박테리아 화합물 및 그의 용도
EP3472152A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacte rials
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
CN110831630A (zh) 2017-03-01 2020-02-21 爱尔兰詹森科学公司 组合疗法
AU2018298855B2 (en) 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
EP4028399B1 (en) 2019-09-13 2024-02-14 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
CA3151712A1 (en) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
BR112022005068A2 (pt) 2019-09-30 2022-09-06 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos de 4-quinolinona
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
PE20221725A1 (es) 2019-12-27 2022-11-04 Tecnimede Sociedade Tecnico Medicinal Sa Nuevos compuestos farmaceuticos
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
JP2023532981A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
BR112023000220A2 (pt) 2020-07-09 2023-01-31 Janssen Pharmaceutica Nv Formulações de longa ação
WO2022008645A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
US20230346770A1 (en) 2020-11-12 2023-11-02 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
MX2023010947A (es) 2021-03-16 2023-11-29 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
KR20230158046A (ko) 2021-03-17 2023-11-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
US20240182495A1 (en) 2021-03-17 2024-06-06 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3223626A1 (en) 2021-06-29 2023-01-05 Augusto Eugenio Pardal Filipe Heterocyclic compounds for the treatment of tuberculosis
CA3234515A1 (en) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用
EP4593834A1 (en) 2022-09-28 2025-08-06 JANSSEN Pharmaceutica NV Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CR20250175A (es) * 2022-11-15 2025-05-27 Lilly Co Eli Agonistas de ahr
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria
WO2025181475A1 (en) 2024-02-27 2025-09-04 The University Of Liverpool Novel tuberculosis sterilization formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6172084B1 (en) * 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU6645198A (en) * 1998-01-23 1999-08-09 Fire Armour Pte Ltd Nozzle with axially and perpendicularly directed apertures
WO1999037635A1 (en) * 1998-01-26 1999-07-29 Smithkline Beecham Plc Quinoline derivatives as antibacterials
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
FR14C0060I2 (fr) 2015-11-20
TWI323730B (en) 2010-04-21
ATE463482T1 (de) 2010-04-15
RS52431B (sr) 2013-02-28
BE2014C051I2 (pl) 2022-08-09
HUS1400047I1 (hu) 2016-09-28
KR20050033607A (ko) 2005-04-12
AU2003262529A1 (en) 2004-02-16
FR14C0060I1 (pl) 2014-10-10
CN101070304B (zh) 2011-10-26
PL222801B1 (pl) 2016-09-30
DE60332023D1 (de) 2010-05-20
NO2014021I2 (pl) 2014-08-20
BR0312927A (pt) 2005-07-12
TW200410939A (en) 2004-07-01
DK2301544T3 (da) 2013-01-02
EP2301544A1 (en) 2011-03-30
SI2301544T1 (sl) 2013-01-31
NO2014021I1 (no) 2014-08-20
AP2005003210A0 (en) 2005-03-31
HK1113795A1 (en) 2008-10-17
HRP20120190A8 (hr) 2012-07-31
ES2343458T3 (es) 2010-08-02
CA2493225A1 (en) 2004-02-05
MXPA05001052A (es) 2005-04-08
CN1325475C (zh) 2007-07-11
DK1527050T3 (da) 2010-07-19
EP2301544B1 (en) 2012-09-19
IL202655A (en) 2012-04-30
CA2493225C (en) 2012-03-20
MEP9208A (en) 2010-06-10
AU2003262529B2 (en) 2009-11-19
CY1111882T1 (el) 2015-11-04
HRP20050045B1 (hr) 2013-09-30
IS2914B (is) 2014-12-15
ES2395237T3 (es) 2013-02-11
AR040673A1 (es) 2005-04-13
KR100733577B1 (ko) 2007-06-29
HRP20120190A2 (hr) 2012-05-31
JP4484703B2 (ja) 2010-06-16
CY1113497T1 (el) 2016-06-22
IL166457A (en) 2011-10-31
BRPI0312927B8 (pt) 2021-05-25
CN101070304A (zh) 2007-11-14
HK1083496A1 (en) 2006-07-07
IL166457A0 (en) 2006-01-15
HRP20120190B1 (hr) 2017-06-02
HRP20050045A2 (en) 2006-06-30
WO2004011436A1 (en) 2004-02-05
CY2014033I1 (el) 2016-04-13
IS7620A (is) 2004-12-29
PT1527050E (pt) 2010-06-22
UA82198C2 (uk) 2008-03-25
JP2006504658A (ja) 2006-02-09
EP1527050B1 (en) 2010-04-07
US7498343B2 (en) 2009-03-03
SI1527050T1 (sl) 2010-08-31
AP2421A (en) 2012-06-08
EA008937B1 (ru) 2007-10-26
EA200500257A1 (ru) 2005-06-30
CN1671667A (zh) 2005-09-21
MY143564A (en) 2011-05-31
NO20050476L (no) 2005-01-27
BRPI0312927B1 (pt) 2018-07-10
NZ538391A (en) 2005-10-28
LU92520I2 (fr) 2015-11-02
RS20050058A (sr) 2007-06-04
EP1527050A1 (en) 2005-05-04
ZA200500680B (en) 2006-08-30
US20050148581A1 (en) 2005-07-07
PT2301544E (pt) 2012-12-10
NO329935B1 (no) 2011-01-24
NL300684I2 (pl) 2016-10-11
ME00131B (me) 2010-10-10
CY2014033I2 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
HUS1400047I1 (hu) Kinolin származékok és azok alkalmazása mikrobakteriális inhibitorként
IL177012A0 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
SI1592686T1 (sl) Inhibitorji giraze in njihova uporaba
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
IL173986A0 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2003303128A8 (en) Inhibitors and methods of use thereof
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
PL377413A1 (pl) Pochodne piryd-2-onu i sposoby ich zastosowania
AU2003215756A1 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
AU2003269421A8 (en) Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
PL374581A1 (pl) Diaminotiazole przydatne jako selektywne inhibitory CDK4
AP2006003693A0 (en) Substituted quinolines and their use as mycobacterial inhibitors
AP1963A (en) Substituted pyrrole derivatives and their use as HMG-co inhibitors
PL380189A3 (pl) Azolidynokarbonitryle i ich zastosowanie jako inhibitory DPP-IV
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
EG24415A (en) Quinoline derivatives
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors
GB0511267D0 (en) Indol derivatives and their use as kinase inhibitors
HK1090358A (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
SI1525200T1 (sl) 2-(3-aminoaril)amino-4-aril-tiazoli in njihova uporaba kot inhibitorji c-kit